# Liying Biotech

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/liying-biotech

- Industry: Biotechnology
- Headquarters: Shenzhen, China
- Website: www.lybio.com
- Latest round: Angel (Apr 3, 2023)
- Investors on record: 4

## About

Established in 2022 and based in Shenzhen, China, Liying Bio operates as a biotech company that focuses on the design adaptation, and production of protein products. Ying Zhang, the founder of the company graduated from the Institute of Cancer Research, University of London, used to work in the National Institute for Medical Research, Francis Crick Institute, and Oxford Universit. The company cooperates with the Affiliated Hospital of Guangdong Medical University. In June 2023, the company jointly established a natural sweetener research center with Hubei University. In December 2024, Liying Bio raised a series A funding for approximately CNY 100 million.

The company's main business is the research and development of protein biological products. The main product is recombinant triple-helix humanized collagen. The company has also developed artificial intelligence-assisted protein design platform, production-end strain transformation platform, B cell high-performance antibody discovery platform and other platforms. The products can be used in antibody drugs, bioenzyme preparations, mRNA vaccines, medical beauty and other fields.

The company generates revenue by providing protein biological products and platforms.

## Funding rounds

- Angel, Apr 3, 2023 — Goldport Capital, Dymind Biotech, Wuxi Best Precision Machinery Co., Ltd, Shenzhen Weiguang Biological Products Co.,Ltd.

## Investors

- Goldport Capital (https://capitalatlas.ai/funds/goldport-capital) — Angel
- Dymind Biotech — Angel
- Wuxi Best Precision Machinery Co., Ltd — Angel
- Shenzhen Weiguang Biological Products Co.,Ltd. — Angel